Table 3.

Overall clinical outcomes in the TDF alone, TDF+LAM, and TDF+ETV therapy groups

	TDF (n=12)	TDF+LAM (n=19)	TDF+ETV (n=42)	P-value
HBeAg seroconversion (n=64, [n ,%])	0/8 (0)	2/17 (11.8)	4/39 (10.3)	0.161
VR (n, %)	9/12 (75.0)	19/19 (100)	35/42 (83.3)	0.099
VBT (n, %)	1 (8.3)	0 (0)	1 (2.4)	0.222
PVR (n, %)	5 (41.7%)	5 (26.3)	20 (47.6)	0.293
ALT normalization (n=23, [n, %])	2/4 (50)	2/3 (66.7)	10/16 (62.5)	0.879

Values are presented as n (%) unless otherwise indicated.

TDF, tenofovir disoproxil fumarate; ETV, entecavir; LAM, lamivudine; HBeAg, hepatitis B e antigen; VR, virologic response; VBT, virological breakthrough; PVR, partial virologic response; ALT, alanine transaminase.